Enterprise Value
0.00
Cash
123.6M
Avg Qtr Burn
N/A
Short % of Float
2.05%
Insider Ownership
0.16%
Institutional Own.
82.58%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KIN-7136 (MEK inhibitor) +/- exarafenib Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1 Update | |
Phase 1 Update | ||
Exarafenib (KN-2787) +/- binimetinib Details Cancer, Solid tumor/s, Melanoma | Phase 1 Update |